Two Sigma Investments’s Checkpoint Therapeutics CKPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-71,727
| Closed | -$290K | – | 3222 |
|
|
2025
Q1 | $290K | Sell |
71,727
-1,305
| -2% | -$4.35K | ﹤0.01% | 2730 |
|
|
2024
Q4 | $234K | Buy |
73,032
+31,002
| +74% | +$105K | ﹤0.01% | 2822 |
|
|
2024
Q3 | $94.1K | Buy |
42,030
+20,403
| +94% | +$47.1K | ﹤0.01% | 2906 |
|
|
2024
Q2 | $46.5K | Buy |
+21,627
| New | +$38.5K | ﹤0.01% | 2892 |
|
|
2022
Q4 | – | Sell |
-4,610
| Closed | -$48K | – | 2826 |
|
|
2022
Q3 | $48K | Sell |
4,610
-7,426
| -62% | -$88.5K | ﹤0.01% | 2321 |
|
|
2022
Q2 | $124K | Sell |
12,036
-25,669
| -68% | -$336K | ﹤0.01% | 2245 |
|
|
2022
Q1 | $667K | Buy |
+37,705
| New | +$810K | ﹤0.01% | 1885 |
|
|
2021
Q4 | – | Sell |
-29,983
| Closed | -$989K | – | 4347 |
|
|
2021
Q3 | $989K | Buy |
29,983
+10,037
| +50% | +$297K | ﹤0.01% | 2632 |
|
|
2021
Q2 | $588K | Sell |
19,946
-9,131
| -31% | -$253K | ﹤0.01% | 2957 |
|
|
2021
Q1 | $913K | Buy |
29,077
+14,676
| +102% | +$492K | ﹤0.01% | 2404 |
|
|
2020
Q4 | $382K | Buy |
+14,401
| New | +$364K | ﹤0.01% | 2687 |
|
Two Sigma Investments's CKPT Position: Q2 2025 in Review
Two Sigma Investments sold out of Checkpoint Therapeutics (CKPT) in Q2 2025, closing a stake of 71,727 shares — an estimated $290K sold.
Two Sigma Investments first reported a position in CKPT in Q4 2020 and held it in 11 quarters. The position peaked at $989K in Q3 2021. 0 funds tracked by Wall St. Rank hold CKPT as of Q2 2025.
- Two Sigma Investments reported no remaining Checkpoint Therapeutics position as of Q2 2025 after selling out during the quarter.
- Two Sigma Investments sold 71,727 Checkpoint Therapeutics shares in Q2 2025, an estimated $290K.
- Two Sigma Investments first reported a position in Checkpoint Therapeutics in Q4 2020 and held it in 11 quarters.
- Two Sigma Investments's Checkpoint Therapeutics position peaked at $989K in Q3 2021.
- 0 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2025.
Based on Two Sigma Investments's 13F filing for Q2 2025, filed 14 Aug 2025.